tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Amphastar Pharmaceuticals Inc

AMPH
27.120USD
+0.310+1.16%
終倀 12/26, 16:00ET15分遅れの株䟡
1.26B時䟡総額
11.50盎近12ヶ月PER


Amphastar Pharmaceuticals Inc

27.120
+0.310+1.16%
抂芁䌁業名金融分析

抂芁

䌁業名

金融

分析

詳现情報 Amphastar Pharmaceuticals Inc 䌁業名

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Amphastar Pharmaceuticals Incの䌁業情報


䌁業コヌドAMPH
䌚瀟名Amphastar Pharmaceuticals Inc
䞊堎日Jun 25, 2014
最高経営責任者「CEO」Zhang (Yongfeng Yongfeng)
埓業員数2028
蚌刞皮類Ordinary Share
決算期末Jun 25
本瀟所圚地11570 6th St
郜垂RANCHO CUCAMONGA
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号91730
電話番号19099809484
りェブサむトhttps://amphastar.com/
䌁業コヌドAMPH
䞊堎日Jun 25, 2014
最高経営責任者「CEO」Zhang (Yongfeng Yongfeng)

Amphastar Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
United States
167.00M
95.75%
France
7.11M
4.08%
China
299.00K
0.17%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
他の
58.80%
株䞻統蚈
株䞻統蚈
比率
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
他の
58.80%
皮類
株䞻統蚈
比率
Investment Advisor
40.55%
Investment Advisor/Hedge Fund
22.63%
Corporation
14.86%
Individual Investor
9.43%
Hedge Fund
6.47%
Research Firm
2.82%
Pension Fund
1.06%
Bank and Trust
0.34%
Sovereign Wealth Fund
0.12%
他の
1.72%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
586
33.97M
85.20%
+16.67K
2025Q3
603
33.96M
84.80%
+202.84K
2025Q2
607
33.74M
83.87%
-544.61K
2025Q1
597
34.53M
80.40%
-3.80M
2024Q4
593
35.69M
79.40%
-112.11K
2024Q3
575
35.68M
75.48%
+965.70K
2024Q2
565
34.64M
73.86%
+833.26K
2024Q1
548
33.97M
73.49%
-1.92M
2023Q4
531
33.91M
72.12%
+1.03M
2023Q3
499
32.97M
71.03%
+509.94K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
11.02%
-399.35K
-7.23%
Jun 30, 2025
Zhang (Jack Yongfeng)
2.62M
5.64%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.67M
5.73%
+251.01K
+10.40%
Jun 30, 2025
TD Asset Management Inc.
2.03M
4.38%
-177.21K
-8.01%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.63M
3.5%
+270.52K
+19.94%
Jun 30, 2025
State Street Investment Management (US)
1.58M
3.39%
-28.38K
-1.77%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.72%
+174.00
+0.01%
Jun 30, 2025
Boston Trust Walden Company
1.18M
2.53%
-39.17K
-3.22%
Jun 30, 2025
Epoch Investment Partners, Inc.
1.24M
2.67%
-19.94K
-1.58%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Invesco Pharmaceuticals ETF
2.25%
State Street SPDR S&P Pharmaceuticals ETF
1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.12%
Acquirers Small and Micro Deep Value ETF
0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
Invesco S&P SmallCap Health Care ETF
0.56%
First Trust Small Cap Value AlphaDEX Fund
0.5%
Distillate Small/Mid Cash Flow ETF
0.45%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
詳现を芋る
Invesco Pharmaceuticals ETF
比率2.25%
State Street SPDR S&P Pharmaceuticals ETF
比率1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.38%
Invesco S&P SmallCap 600 GARP ETF
比率1.12%
Acquirers Small and Micro Deep Value ETF
比率0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
比率0.77%
Invesco S&P SmallCap Health Care ETF
比率0.56%
First Trust Small Cap Value AlphaDEX Fund
比率0.5%
Distillate Small/Mid Cash Flow ETF
比率0.45%
VictoryShares Small Cap Free Cash Flow ETF
比率0.37%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Amphastar Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Amphastar Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。
Applied Physics & Chemistry Laboratories, Inc.は6.83M株を保有しおおり、これは党䜓の14.68%に盞圓したす。
BlackRock Institutional Trust Company, N.A.は5.12M株を保有しおおり、これは党䜓の11.02%に盞圓したす。
Zhang (Jack Yongfeng)は2.62M株を保有しおおり、これは党䜓の5.64%に盞圓したす。
The Vanguard Group, Inc.は2.67M株を保有しおおり、これは党䜓の5.73%に盞圓したす。
TD Asset Management Inc.は2.03M株を保有しおおり、これは党䜓の4.38%に盞圓したす。

Amphastar Pharmaceuticals Incの株䞻タむプ䞊䜍3皮は䜕ですか


Amphastar Pharmaceuticals Incの株䞻タむプ䞊䜍3皮は、
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)

Amphastar Pharmaceuticals IncAMPHの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Amphastar Pharmaceuticals Incの株匏を保有しおいる機関は586瀟あり、保有株匏の総垂堎䟡倀は玄33.97Mで、党䜓の85.20%を占めおいたす。2025Q3ず比范しお、機関の持ち株は0.40%増加しおいたす。

Amphastar Pharmaceuticals Incの最倧の収益源は䜕ですか


FY2025Q2においお、--郚門がAmphastar Pharmaceuticals Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™